Diminished myelin-specific T cell activation associated with increase in CTLA4 and Fas molecules in multiple sclerosis patients treated with IFN-β

Journal of Interferon and Cytokine Research

Volumn 27, Issue 10, 2007, Pages 865-873

  Hallal Longo, Dannie E M ^a   Mirandola, Sandra R ^a   Oliveira, Elaine C ^a   Farias, Alessandro S ^a   Pereira, Fernanda G ^a   Metze, Irene L ^a   Brandão, Carlos Otavio ^a   Ruocco, Heloísa H ^a   Damasceno, Benito P ^a   Santos, Leonilda M B ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; INTERFERON BETA SERINE; MYELIN; MYELIN BASIC PROTEIN;

ADULT; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT DISEASE; T LYMPHOCYTE ACTIVATION; WHITE MATTER;

ADULT; ANTIGENS, CD; ANTIGENS, CD95; ANTIGENS, DIFFERENTIATION; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; FEMALE; HUMANS; INTERFERON-BETA; LYMPHOCYTE ACTIVATION; MALE; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; MYELIN SHEATH; SOLUBILITY; T-LYMPHOCYTES;

EID: 35648938148     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2007.0018     Document Type: Article

References (44)

1. Kappos L, Traboulsee A, Constantinescu C, Eralinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-953.
2. Sospedra M, Martin R. Immunology of multiple sclerosis [Review]. Annu. Rev. Immunol. 2005;23:683-747.
3. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation [Review]. Annu. Rev. Immunol. 1996;14:233-258.
4. Walunas TL, Bluestone JA. CTLA-4 regulates tolerance induction and T cell differentiation in vivo. J. Immunol. 1998;160:3855-3860.
5. Gribben JG, Freeman GJ, Boussiotis VA, Rennert P, Jellis CL, Greenfield E, Barber M, Restivo VA Jr, Ke X, Gray GS, Nadler LM. CTLA4 mediates antigen-specific apoptosis of human T cells. Proc. Natl. Acad. Sci. USA 1995;92:811-815.
6. Li W, Carper K, Zheng XX, Kuhr CS, Reyes JD, Liang Y, Perkins DL, Thomson AW, Perkins JD. The role of Foxp3+ regulatory T cells in liver transplant tolerance. Transplant. Proc. 2006;38:3205-3206.
7. Oehm A, Behrmann I, Falk W, Pawlita M, Maier G, Klas C, Li-Weber M, Richards S, Dhein J, Trauth BC, et al. Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily. Sequence identity with the Fas antigen. J. Biol. Chem. 1992;267:10709-10715.
8. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
9. Russell JH, Rush B, Weaver C, Wang R. Mature T cells of autoimmune lpr/lpr mice have a defect in antigen-stimulated suicide. Proc. Natl. Acad. Sci. USA 1993;90:4409-4413.
10. Russell JH, Wang R. Autoimmune gld mutation uncouples suicide and cytokine/proliferation pathways in activated, mature T cells. Eur. J. Immunol. 1993;23:2379-2382.
11. Dowling P, Shang G, Raval S, Menonna J, Cook S, Husar W. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med. 1996;184:1513-1518.
12. Bauer J, Bradl M, Hickley WF, Forss-Petter S, Breitschopf H, Linington C, Wekerle H, Lassmann H. T-cell apoptosis in inflammatory brain lesions: destruction of T cells does not depend on antigen recognition. Am. J. Pathol. 1998;153:715-724.
13. Tischner D, Weishaupt A, van den Brandt J, Ip CW, Kerkau T, Gold R, Reichardt HM. Antigen therapy of experimental autoimmune encephalomyelitis selectively induces apoptosis of pathogenic T cells. J. Neuroimmunol. 2007;183:146-150.
14. Lopatinskaya L, Zwemmer J, Uitdehaag B, Lucas K, Polman C, Nagelkerken L. Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years. Mult. Scler. 2006;12:704-709.
15. Semra YK, Seidi OA, Sharief MK. Disease activity in multiple sclerosis correlates with T lymphocyte expression of the inhibitor of apoptosis proteins. J. Neuroimmunol. 2002;122:159-166.
16. + T cells in multiple sclerosis. J. Neuroimmunol. 2006;180:147-158.
17. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tourtellotte WW. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 1983;13:227-231.
18. Deibler GE, Martenson RE, Kies MW. Large-scale preparation of myelin basic protein from central nervous tissue of several mammalian species. Prep. Biochem. 1972;2:139-165.
19. Norton WT. Biochemistry of myelin. Adv. Neurol. 1981;31:93-121.
20. Norton WT, Poduslo SE. Myelination in rat brain: method of myelin isolation. J. Neurochem. 1973;21:749-757.
21. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990;346:183-187.
22. Hafler DA, Weiner HL. MS: a CNS and systemic autoimmune disease. Immunol. Today 1989;10:104-107.
23. Hallal DE, Farias AS, Oliveira EC, Diaz-Bardales BM, Brandao CO, Protti GG, Pereira FG, Metze IL, Santos LM. Costimulatory molecule expression on leukocytes from mice with experimental autoimmune encephalomyelitis treated with IFN-β. Interferon Cytokine Res. 2003;23:293-298.
24. Killestein J, Hintzen RQ, Uitdehaag BM, Baars PA, Roos MT, van Lier RA, Polman CH. Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta. J. Neuroimmunol. 2002;133:217-224.
25. Teige I, Liu Y, Issazadeh-Navikas S. IFN-beta inhibits T cell activation capacity of central nervous system APCs. J. Immunol. 2006;177:3542-3553.
26. Lopez C, Comabella M, Al-zayat H, Tintore M, Montalban X. Altered maturation of circulating dendritic cells in primary progressive MS patients. J. Neuroimmunol. 2006;175:183-191.
27. Gniadek P, Aktas O, Wandinger KP, Bellmann-Strobl J, Wengert O, Weber A, von WussowP, Obert HJ, Zipp F. Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in MS patients. J. Neuroimmunol. 2003;137:187-196.
28. Hurwitz AA, Sullivan TJ, Sobel RA, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice. Proc. Natl. Acad. Sci. USA 2002;99:3013-3017.
29. Karandikar NJ, Eagar TN, Vanderlugt CL, Bluestone JA, Miller SD. CTLA-4 downregulates epitope spreading and mediates remission in relapsing experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2000;109:173-180.
30. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity 1996;4:535-543.
31. Perez VL, Van Parijs L, Biuckians A, Zheng XX, Strom TB, Abbas AK. Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 1997;6:411-417.
32. Coyle AJ, Gutierrez-Ramos JC. The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T function. Nat. Immunol. 2001;2:203-209.
33. Khoury SJ, Sayegh MH. The roles of the new negative T cell costimulatory pathways in regulating autoimmunity [Review]. Immunity 2004;20:529-38.
34. Chen W, Jin W, Wahl SM. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J. Exp. Med. 1998;188:1849-1857.
35. Oida T, Xu L, Weiner HL, Kitani A, Strober W. TGF-beta-mediated suppression by CD4+CD25+ T cells is facilitated by CTLA-4 signaling. J. Immunol. 2006;177:2331-2319.
36. Zheng SG, Wang JH, Stohl W, Kim KS, Gray JD, Horwitz DA.TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J. Immunol. 2006;176:3321-3329.
37. Scheipers P, Reiser H. Fas-independent death of activated CD4(+) T lymphocytes induced by CTLA-4 crosslinking. Proc. Natl. Acad. Sci. USA 1998;95:10083-10088.
38. Comi C, Leone M, Bonissoni S, DeFranco S, Bottarel F, Mezzatesta C, Chiocchetti A, Perla F, Monaco F, Dianzani U. Defective T cell Fas function in patients with multiple sclerosis. Neurology 2000;55:921-997.
39. Okuda Y, Apatoff BR, Posnett DN. Apoptosis of T cells in peripheral blood and cerebrospinal fluid is associated with disease activity of multiple sclerosis. J. Neuroimmunol. 2006;171:163-170.
40. Lopatinskaya L, Zwemmer J, Uitdehaag B, Lucas K, Polman C, Nagelkerken L. Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years. Mult. Scler. 2006;12:704-709.
41. Sharief MK, Noori MA, Zoukos Y. Reduced expression of the inhibitor of apoptosis proteins in T cells from patients with multiple sclerosis following interferon-beta therapy. J. Neuroimmunol. 2002;129:224-231.
42. Zipp F, Weller M, Calabresi PA, Frank JA, Bash CN, Dichgans J, McFarland HF, Martin R. Increased serum levels of soluble CD95 (APO-1/Fas) in relapsing-remitting multiple sclerosis. Ann. Neurol. 1998;43:116-120.
43. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-1762.
44. Zipp F, Otzelberger K, Dichgans J, Martin R, Weller M. Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis. J. Neuroimmunol. 1998;86:151-154.